Alteration of Basal Ganglia Evoked Responses by Reserpine and L-dopa

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 1976 Sep 29

PMID 826946

Authors

W C Koller

C A Berry

Affiliations

Soon will be listed here.

Abstract

The effects of reserpine and L-Dopa on basal ganglia evoked potentials were investigated in cats. The caudate response resulting from substantia nigra stimulation and the substantia nigra response elicited by globus pallidus stimulation were increased at several hours after the systemic administration of reserpine. L-Dopa in the presence of dopa decarboxylase inhibition (MK-486) depressed these responses and reversed the effect of reserpine at 0.5 h after administration. Reserpine did not reverse the L-Dopa effect. Reserpine and L-Dopa caused no significant change in responses between other basal ganglia structures. These data give evidence that the basal ganglia are major sites for reserpine and L-Dopa action.

References

BARTHOLINI G, Pletscher A . Effect of various decarboxylase inhibitors on the cerebral metabolism of dihydroxyphenylalanine. J Pharm Pharmacol. 1969; 21(5):323-4. DOI: 10.1111/j.2042-7158.1969.tb08258.x. View

Hornykiewicz O . Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev. 1966; 18(2):925-64. View

Carlsson A, Lindqvist M, Magnusson T . 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature. 1957; 180(4596):1200. DOI: 10.1038/1801200a0. View

Bjorklund A, Lindvall O . Dopamine in dendrites of substantia nigra neurons: suggestions for a role in dendritic terminals. Brain Res. 1975; 83(3):531-7. DOI: 10.1016/0006-8993(75)90849-5. View

Moore R, Bhatnagar R, Heller A . Anatomical and chemical studies of a nigro-neostriatal projection in the cat. Brain Res. 1971; 30(1):119-35. DOI: 10.1016/0006-8993(71)90009-6. View

Carlsson A . The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev. 1959; 11(2, Part 2):490-3. View

Connor J . Caudate nucleus neurones: correlation of the effects of substantia nigra stimulaton with iontophoretic dopamine. J Physiol. 1970; 208(3):691-703. PMC: 1348793. DOI: 10.1113/jphysiol.1970.sp009143. View

Nauta W, MEHLER W . Projections of the lentiform nucleus in the monkey. Brain Res. 1966; 1(1):3-42. DOI: 10.1016/0006-8993(66)90103-x. View

POIRIER L, Sourkes T . INFLUENCE OF THE SUBSTANTIA NIGRA ON THE CATECHOLAMINE CONTENT OF THE STRIATUM. Brain. 1965; 88:181-92. DOI: 10.1093/brain/88.1.181. View

10.

Koller W, Berry C . Modification of evoked responses in the caudate nucleus by cholinergic agents. Neuropharmacology. 1976; 15(4):233-8. DOI: 10.1016/0028-3908(76)90069-1. View

11.

Fuxe K . EVIDENCE FOR THE EXISTENCE OF MONOAMINE NEURONS IN THE CENTRAL NERVOUS SYSTEM. IV. DISTRIBUTION OF MONOAMINE NERVE TERMINALS IN THE CENTRAL NERVOUS SYSTEM. Acta Physiol Scand Suppl. 1965; :SUPPL 247:37+. View

12.

Hattori T, McGeer P, Fibiger H, McGeer E . On the source of GABA-containing terminals in the substantia nigra. Electron microscopic autoradiographic and biochemical studies. Brain Res. 1973; 54:103-14. DOI: 10.1016/0006-8993(73)90037-1. View

13.

Bernheimer H . DISTRIBUTION OF HOMOVANILLIC ACID IN THE HUMAN BRAIN. Nature. 1964; 204:587-8. DOI: 10.1038/204587b0. View

14.

BERTLER A, ROSENGREN E . On the distribution in brain of monoamines and of enzymes responsible for their formation. Experientia. 1959; 15:382-4. DOI: 10.1007/BF02158964. View

15.

McLennan H, York D . The action of dopamine on neurones of the caudate nucleus. J Physiol. 1967; 189(3):393-402. PMC: 1396117. DOI: 10.1113/jphysiol.1967.sp008175. View

16.

Ehringer H, Hornykiewicz O . [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]. Klin Wochenschr. 1960; 38:1236-9. DOI: 10.1007/BF01485901. View

17.

Moore K, Von Voigtlander P . The release of H 3 -dopamine from cat brain following electrical stimulation of the substantia nigra and caudate nucleus. Neuropharmacology. 1971; 10(6):733-41. DOI: 10.1016/0028-3908(71)90088-8. View

18.

Guldberg H, Yates C . Effects of chlorpromazine on the metabolism of catecholamines in dog brain. Br J Pharmacol. 1969; 36(3):535-48. PMC: 1703605. DOI: 10.1111/j.1476-5381.1969.tb08009.x. View

19.

DAHLSTROEM A, Fuxe K . EVIDENCE FOR THE EXISTENCE OF MONOAMINE-CONTAINING NEURONS IN THE CENTRAL NERVOUS SYSTEM. I. DEMONSTRATION OF MONOAMINES IN THE CELL BODIES OF BRAIN STEM NEURONS. Acta Physiol Scand Suppl. 1964; :SUPPL 232:1-55. View

20.

Klawans Jr H . The pharmacology of parkinsonism (a review). Dis Nerv Syst. 1968; 29(12):805-16. View